Conference
Phase II trial of the irreversible oral pan-HER inhibitor PF-00299804 (PF) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).
Authors
Le Tourneau C; Winquist E; Hotte SJ; Laurie SA; Soulieres D; Chia SK; Singh S; Wang T; Mormont C; Siu LL
Volume
28
Pagination
pp. 5531-5531
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2010
DOI
10.1200/jco.2010.28.15_suppl.5531
Conference proceedings
Journal of Clinical Oncology
Issue
15_suppl
ISSN
0732-183X